文献速递胸部CT

IIIA-N2期非小细胞肺癌患者术前N亚分类的预后价值

Prognostic Value of Preoperative N Subcategories in Patients with Stage IIIA N2 Non-Small Cell Lung Cancer.
PubMed 文献 · Radiol Cardiothorac Imaging · 2024-01-01

本回顾性研究纳入2015年1月至2021年4月单中心收治的366例病理IIIA-N2期非小细胞肺癌行 upfront 手术患者,按新提出的N描述符将临床N分为六个亚类,评估术前CT预后价值。中位随访37.3个月,复发率55%;多因素分析显示临床N亚类及N1站最大淋巴结短径≥12 mm是RFS和OS的独立预后因素。

要点

  • 术前CT评估N2为单站或多站受累及转移淋巴结最大径,可提供预后信息。
  • 临床N1和cN2b较cN0的RFS风险比分别为1.66和2.11。
  • N1站淋巴结最大径≥12 mm者RFS风险比为1.62。

核心结论

  • 术前CT评估新提出的N亚分类(N2单站与多站受累及转移淋巴结最大径)可提供有用的预后信息,有助于制定最佳治疗策略。

研究设计与样本

  • 单中心回顾性研究,纳入2015年1月至2021年4月病理IIIA-N2期非小细胞肺癌行 upfront 手术患者366例(平均年龄62.0岁±10.1,男性202例[55%]),按新N描述符将临床N分为cN0、cN1a、cN1b、cN2a1、cN2a2和cN2b六个亚类,采用Cox回归分析RFS和OS的预后因素。

诊断标准与关键数值

  • RFS多因素分析:cN1 vs cN0的HR为1.66(95%CI:1.11,2.48),cN2b vs cN0的HR为2.11(95%CI:1.32,3.38),N1站最大淋巴结径≥12 mm的HR为1.62(95%CI:1.15,2.29),临床T分期的HR为1.51(95%CI:1.14,1.99);OS多因素分析:cN1 vs cN0的HR为1.91(95%CI:1.11,3.27),cN2a2 vs cN0的HR为1.89(95%CI:1.13,2.18),cN2b vs cN0的HR为2.02(95%CI:1.07,3.80),N1站淋巴结径的HR为1.75(95%CI:1.12,2.71);临床N1患者按淋巴结大小分层OS的log-rank检验P<.001。

临床应用与阅片要点

  • 术前CT报告可按新N亚分类描述N2为单站或多站受累,并测量N1站最大淋巴结径(阈值12 mm),以反映转移负荷并提供预后信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To evaluate the preoperative risk factors in patients with pathologic IIIA N2 non-small cell lung cancer (NSCLC) who underwent upfront surgery and to evaluate the prognostic value of new N subcategories. Materials and Methods Patients with pathologic stage IIIA N2 NSCLC who underwent upfront surgery in a single tertiary center from January 2015 to April 2021 were retrospectively reviewed. Each patient's clinical N (cN) was assigned to one of six subcategories (cN0, cN1a, cN1b, cN2a1, cN2a2, and cN2b) based on recently proposed N descriptors. Cox regression analysis was used to identify the significant prognostic factors for recurrence-free survival (RFS) and overall survival (OS). Results A total of 366 patients (mean age ± SD, 62.0 years ± 10.1; 202 male patients [55%]) were analyzed. The recurrence rate was 55% (203 of 366 patients) over a median follow-up of 37.3 months. Multivariable analysis demonstrated that cN (hazard ratios [HRs] for cN1 and cN2b compared with cN0, 1.66 [95% CI: 1.11, 2.48] and 2.11 [95% CI: 1.32, 3.38], respectively) and maximum lymph node (LN) size at N1 station (≥12 mm; HR, 1.62 [95% CI: 1.15, 2.29]), in addition to clinical T category (HR, 1.51 [95% CI: 1.14, 1.99]), were independent prognostic factors for RFS. For OS, clinical N subcategories (cN1, cN2a2, and cN2b vs cN0; HRs, 1.91 [95% CI: 1.11, 3.27], 1.89 [95% CI: 1.13, 2.18], and 2.02 [95% CI: 1.07, 3.80], respectively) and LN size at N1 station (HR, 1.75 [95% CI: 1.12, 2.71]) were independent prognostic factors. For clinical N1, OS was further stratified according to LN size (log-rank test, P < .001). Conclusion Assessing the proposed N subcategories by reporting single versus multistation involvement of N2 disease and maximum size of metastatic LN, reflecting metastatic burden, at preoperative CT may offer useful prognostic information for planning optimal treatment strategies. Keywords: CT, Lung, Staging, Non-Small Cell Lung Cancer Supplemental material is available for this article. ©RSNA, 2024.

来源:Radiol Cardiothorac Imaging,查看原文。版权归原作者所有。

引用

  1. Oh NE, Choe J, Yun JK, et al. Prognostic Value of Preoperative N Subcategories in Patients with Stage IIIA N2 Non-Small Cell Lung Cancer. Radiol Cardiothorac Imaging. 2024. PMID: 38990133. doi:10.1148/ryct.230347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。